Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroid hormone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    227 result(s) found for: Thyroid hormone. Displaying page 1 of 12.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-001066-42 Sponsor Protocol Number: GETNE-T1812 Start Date*: 2020-02-20
    Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE)
    Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial
    Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076603 Poorly differentiated thyroid carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071027 Thyroid cancer stage I PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071028 Thyroid cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004451-35 Sponsor Protocol Number: MRTSH01505 Start Date*: 2007-03-13
    Sponsor Name:Genzyme Europe BV
    Full Title: Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multi...
    Medical condition: Nodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the nor...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043808 Thyrotropin LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002419-48 Sponsor Protocol Number: GETNE-T2216 Start Date*: 2023-03-27
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE)
    Full Title: Biomarker Phase II Study Of Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
    Medical condition: Patients with radioiodine-refractory differentiated thyroid cancer (DTC).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002269-47 Sponsor Protocol Number: STH18441 Start Date*: 2015-12-02
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy.
    Medical condition: Iodine-refractory thyroid cancer of papillary, follicular, Hürthle cell or poorly differentiated carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071029 Thyroid cancer stage III PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071030 Thyroid cancer stage IV PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-001455-42 Sponsor Protocol Number: NL56309.091.16 Start Date*: 2016-04-20
    Sponsor Name:Radboud Universitair Medisch Centrum
    Full Title: The influence of metformin and a hypocaloric diet on thyroid radioactive iodide uptake in healthy volunteers: a pilot study
    Medical condition: physiological thyroid function in terms of thyroid iodide uptake and thyroid hormone production knowledge can be extrapolated for treatment of thyroid diseases such as hyperthyroidism and thyroid ...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004535-12 Sponsor Protocol Number: KO-TIP-001 Start Date*: 2016-02-25
    Sponsor Name:Kura Oncology, Inc.
    Full Title: An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations
    Medical condition: Advanced Non-Hematological Malignancies with HRAS mutations
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048683 Advanced cancer LLT
    18.1 10018065 - General disorders and administration site conditions 10071971 H-ras gene mutation PT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005269-15 Sponsor Protocol Number: CO42865 Start Date*: 2022-05-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCER
    Medical condition: RET-mutated Medullary Thyroid Cancer (MTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) PT (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) BE (Prematurely Ended) BG (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004934-32 Sponsor Protocol Number: IRUSZACT0098 Start Date*: 2012-03-07
    Sponsor Name:National Cancer Institute
    Full Title: A phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid cancer.
    Medical condition: Hereditary medullary thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-003687-37 Sponsor Protocol Number: BRD/05/83 Start Date*: 2006-07-24
    Sponsor Name:University College London
    Full Title: HiLo: Multicentre randomised phase III clinical trial of high versus low dose radioiodine, with or without recombinant human thyroid stimulating hormone (rhTSH), for remnant ablation following surg...
    Medical condition: Differentiated thyroid cancer (DTC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-001941-11 Sponsor Protocol Number: 2021-1798 Start Date*: 2021-09-09
    Sponsor Name:Rijnstate hospital
    Full Title: Ultrasound-guided radiofrequency ablation versus radioactive iodine as treatment for hyperthyroidism caused by solitary autonomous thyroid nodules.
    Medical condition: Patients > 18 years with (subclinical) hyperthyroidism caused by a solitary hyperactive thyroid nodules, either as a solitary hyperactive node in an otherwise normal thyroid gland or as a single hy...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004860 10043753 Thyroid nodule (toxic) LLT
    20.0 100000004860 10043791 Thyrotoxicosis from ectopic thyroid nodule LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-003099-39 Sponsor Protocol Number: LWH0604 Start Date*: 2008-08-21
    Sponsor Name:Liverpool Women's NHS Foundation Trust Hospital
    Full Title: A Randomised Controlled Trial of Thyroxine in Preterm Infants Under 28 weeks' Gestation.
    Medical condition: Hypothyroidism is a condition where there is a lack of thyroid hormone in the body. Thyroid hormones are important for normal brain development and growth. Children who are born with low thyroid ho...
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-000209-35 Sponsor Protocol Number: 7805 Start Date*: 2016-08-24
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Adjuvant rituximab – a potential treatment for the young patient with Graves’ hyperthyroidism
    Medical condition: Graves' hyperthyroidism
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001980-53 Sponsor Protocol Number: GORTX-2012 Start Date*: 2012-05-15
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Preliminary study on the effectiveness of low doses of Rituximab in patients with Graves’ orbitopathy (GO) poorly responding to immunosuppressive steroid treatment.
    Medical condition: Active moderate to severe Graves Orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10060742 Endocrine ophthalmopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001006-41 Sponsor Protocol Number: ETHIC_pilot Start Date*: 2018-09-03
    Sponsor Name:Academisch Medisch Centrum
    Full Title: The Efficacy of TRH in Intensive Care patients; a dose finding study
    Medical condition: Non thyroidal illness syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012007-25 Sponsor Protocol Number: BAY43-9006/14295 Start Date*: 2009-10-21
    Sponsor Name:Bayer AG
    Full Title: A Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
    Medical condition: Differentiated thyroid cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066136 Huerthle cell carcinoma PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed) FR (Completed) DK (Completed) SE (Completed) BE (Completed) AT (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-005050-11 Sponsor Protocol Number: SeMMIviD Start Date*: 2019-03-08
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Effects of Selenium and cholecalciferol on hyperthyroidism due to Graves' disease treated with methimazole: a randomized, clinical, open label, pilot trial
    Medical condition: Graves' disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10020850 Hyperthyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000178-20 Sponsor Protocol Number: MCT8-2014-1 Start Date*: 2015-08-12
    Sponsor Name:Erasmus Medical Centre
    Full Title: Thyroid hormone analog therapy of patients with severe psychomotor retardation caused by mutations in the MCT8 thyroid hormone transporter: The Triac Trial.
    Medical condition: This therapuetical trial will be conducted in patient with the Allan-Herndon-Dudley Syndrome (AHDS), casued by mutations in the thyroid hormone transporter MCT8. This results in the characteristic ...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: BE (Completed) CZ (Completed) DE (Completed) IT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000942-39 Sponsor Protocol Number: NL34476.068.11 Start Date*: 2011-06-20
    Sponsor Name:CTMM, the Center for Translational Molecular Medicine
    Full Title: Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.
    Medical condition: This trial includes overweight patients with both hypothyroidism and type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000284-32 Sponsor Protocol Number: SHP634-401 Start Date*: 2018-02-05
    Sponsor Name:Shire Human Genetic Therapies, Inc.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinan...
    Medical condition: Hypoparathyroidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10051315 Congenital hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10075900 Primary hypoparathyroidism PT
    20.0 10014698 - Endocrine disorders 10021041 Hypoparathyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) SE (Completed) DK (Completed) ES (Completed) NO (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 08:19:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA